799 results match your criteria Blood Cancer Journal [Journal]


Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma.

Blood Cancer J 2019 Feb 19;9(3):22. Epub 2019 Feb 19.

Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Treatment with programmed death-1 (PD-1) blocking antibodies results in high overall response rates in refractory and relapsed classical Hodgkin lymphoma (cHL) patients, indicating that PD-1/PD-1 ligand interactions are integral to progression of this disease. Given the genetically driven increased PD-L1/2 expression in HL, we hypothesized that reverse signaling through PD-1 ligands may be a potential mechanism contributing to the growth and survival of Hodgkin Reed-Sternberg (HRS) cells in cHL. Our data show that engagement of PD-L1 using an agonistic monoclonal antibody increases cell survival and proliferation and reduces apoptosis in HL cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0185-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381098PMC
February 2019

Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing.

Blood Cancer J 2019 Feb 19;9(3):21. Epub 2019 Feb 19.

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Microarray analysis of the multiple myeloma (MM) miRNome has unraveled the differential expression of miRNAs in cytogenetic subgroups, their involvement in the tumor biology and their effectiveness in prognostic models. Herein, the small RNA transcriptional landscape in MM has been investigated exploiting the possibilities offered by small RNA-seq, including accurate quantification of known mature species, discovery and characterization of isomiRs, and miRNA-offset RNAs (moRNAs). Matched small RNA-seq and miRNA GeneChip microarray expression profiles were obtained in a representative panel of 30 primary MM tumors, fully characterized for genomic aberrations and mutations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0184-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381125PMC
February 2019

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.

Blood Cancer J 2019 Feb 11;9(2):19. Epub 2019 Feb 11.

Division of Hematology, Mayo Clinic, Scottsdale, AZ, USA.

To understand immunomodulatory drug (IMiD) resistance in multiple myeloma (MM), we created isogenic human multiple myeloma cell lines (HMCLs) sensitive and resistant to lenalidomide, respectively. Four HMCLs were demonstrated to be resistant to all IMiDs including lenalidomide, pomalidomide, and CC-220, but not to Bortezomib. In three HMLCs (MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0173-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370766PMC
February 2019
1 Read

Validation of the Mayo alliance prognostic system for mastocytosis.

Blood Cancer J 2019 Feb 11;9(2):18. Epub 2019 Feb 11.

CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi, Firenze, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0179-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370807PMC
February 2019

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.

Blood Cancer J 2019 Feb 4;9(2):17. Epub 2019 Feb 4.

Sarah Cannon Research Institute, Nashville, TN, USA.

FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent. This phase I study assessed safety, tolerability, maximum tolerated dose (MTD), anti-tumor activity, and pharmacokinetics of DFRF4539A in patients with relapsed/refractory multiple myeloma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0178-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362066PMC
February 2019
1 Read
2.884 Impact Factor

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients.

Blood Cancer J 2019 Feb 4;9(2):15. Epub 2019 Feb 4.

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.

Caucasian Americans (CA) compared with African Americans (AA) have a twofold increased incidence of multiple myeloma (MM) and have an earlier age of diagnosis. However, there is sparse information regarding underlying biological differences across racial/ethnic groups. We characterized genetic alterations using a targeted next-generation sequencing assay called myTYPE, developed at MSKCC, allowing capture of somatic mutations, IgH translocations, gains/losses, and hyperdiploidy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0177-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361959PMC
February 2019
1 Read

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients.

Blood Cancer J 2019 Jan 29;9(2):13. Epub 2019 Jan 29.

Department of Hematology, Oncology and Rheumatology, Heidelberg University, Heidelberg, Germany.

Immunomodulatory drugs (IMIDs) are very effective in the treatment of multiple myeloma (MM). The description of their cereblon-mediated mechanism of action was a hallmark in MM research. Although the importance of IMID-induced degradation of cereblon-binding proteins is well described in vitro, the prognostic value of their expression levels in MM cells is less clear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0174-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351644PMC
January 2019

CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas.

Blood Cancer J 2019 Jan 29;9(2):14. Epub 2019 Jan 29.

Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0171-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351628PMC
January 2019

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model.

Blood Cancer J 2019 Jan 25;9(2):12. Epub 2019 Jan 25.

Departments of Divisions of Hematology, Mayo Clinic, Rochester, MN, USA.

Among 1306 patients with primary myelofibrosis (PMF), we sought to identify risk factors that predicted leukemic transformation (LT) in the first 5 years of disease and also over the course of the disease. 149 (11%) LT were documented; patients who subsequently developed LT (n = 149), compared to those who remained in chronic phase disease (n = 1,157), were more likely to be males (p = 0.02) and display higher circulating blasts (p = 0. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-019-0175-y
Publisher Site
http://dx.doi.org/10.1038/s41408-019-0175-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347609PMC
January 2019
10 Reads

The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL.

Blood Cancer J 2019 Jan 22;9(2):10. Epub 2019 Jan 22.

Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Outcomes of pediatric and young adult patients diagnosed with acute lymphoblastic leukemia (ALL) have improved significantly in the past few decades. Treatment advances have provided 5-year survival rates ranging from 78 to 91% depending on the age at diagnosis. However, approximately 2-3% of patients will present with refractory disease that is unresponsive to chemotherapy, and 10-15% of patients will relapse. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0164-6
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0164-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342933PMC
January 2019
5 Reads

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.

Blood Cancer J 2019 Jan 17;9(2). Epub 2019 Jan 17.

Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital Herlev, Herlev, Denmark.

Mutations in exon 9 of the calreticulin gene (CALR) frequently occur in patients with chronic myeloproliferative neoplasms (MPN). Patients exhibit spontaneous cellular immune responses to epitopes derived from the mutant CALR C-terminus, and CALR-mutant-specific T cells recognize autologous CALR-mutant malignant cells. This study investigated whether CALR-mutant-specific T cells occur naturally in CALRwt MPN-patients and in healthy individuals. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0166-4
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0166-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336769PMC
January 2019
9 Reads

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

Blood Cancer J 2019 Jan 16;9(2). Epub 2019 Jan 16.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Late relapse, defined as relapse arising after at least 5 years of remission, is rare and occurs in 1-3% of patients with acute myeloid leukemia (AML). The underlying mechanisms of late relapse remain poorly understood. We identified patients with AML who achieved remission with standard induction chemotherapy and relapsed after at least five years of remission (n = 15). Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-019-0170-3
Publisher Site
http://dx.doi.org/10.1038/s41408-019-0170-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335405PMC
January 2019
11 Reads
2.884 Impact Factor

Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1.

Blood Cancer J 2019 Jan 15;9(2). Epub 2019 Jan 15.

Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, ON, Canada.

CD123 (IL-3Rα) is frequently expressed by malignant Hodgkin lymphoma (HL) cells. Naked monoclonal antibodies (mAb) against HL lack clinical benefit, partially due to absence of natural killer (NK) cells in the tumor microenvironment. Here we show that the combination of a fully humanized anti-CD123 mAb (CSL362) and high-affinity Fcγ-receptor NK-92 cells (haNK) effectively target and kill HL cells in vitro. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0168-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333842PMC
January 2019
1 Read

The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia.

Blood Cancer J 2019 Jan 15;9(2). Epub 2019 Jan 15.

Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0169-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333797PMC
January 2019
2 Reads

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.

Blood Cancer J 2019 Jan 15;9(2). Epub 2019 Jan 15.

The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

First-generation bromodomain extra-terminal protein (BETP) inhibitors (BETi) (e.g., OTX015) that disrupt binding of BETP BRD4 to chromatin transcriptionally attenuate AML-relevant progrowth and prosurvival oncoproteins. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0165-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333829PMC
January 2019
1 Read

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.

Blood Cancer J 2019 Jan 4;9(1). Epub 2019 Jan 4.

Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Proteasome (PIs) and hystone deacetylase inhibitors (HDACis) have previously shown synergistic activity in the treatment of relapesed/refractory multiple myeloma (RRMM) patients. In this phase 1 study, we combined carfilzomib, a second generation PI, with panobinostat, a HDACi, to determine the maximum tolerated dose (MTD) of the combination (CarPan) and assess safety and efficacy among RRMM patients. Thirty-two patients (median of 4 prior lines of therapy) were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0154-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320362PMC
January 2019
8 Reads

Molecular signatures of multiple myeloma progression through single cell RNA-Seq.

Blood Cancer J 2019 Jan 3;9(1). Epub 2019 Jan 3.

Genome Analysis Core, Medical Genome Facility, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.

We used single cell RNA-Seq to examine molecular heterogeneity in multiple myeloma (MM) in 597 CD138 positive cells from bone marrow aspirates of 15 patients at different stages of disease progression. 790 genes were selected by coefficient of variation (CV) method and organized cells into four groups (L1-L4) using unsupervised clustering. Plasma cells from each patient clustered into at least two groups based on gene expression signature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0160-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318319PMC
January 2019
1 Read

Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology.

Blood Cancer J 2018 Dec 21;9(1). Epub 2018 Dec 21.

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.

The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) genome-wide association study (GWAS) data sets, totalling 11,734 cases and 29,468 controls. A significant genetic correlation between these two B-cell malignancies was shown (R = 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0162-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315026PMC
December 2018
8 Reads
2.884 Impact Factor

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome.

Blood Cancer J 2018 Dec 11;8(12):125. Epub 2018 Dec 11.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Overall survival (OS) of multiple myeloma has improved remarkably over time, with the recent Intergroupe Francophone du Myelome (IFM) 2009 randomized trial reporting a 4-year OS rate of approximately 82% in patients receiving modern therapy. However, survival estimates from clinical trials may overestimate outcomes seen in clinical practice even with the adjustment for age and other key characteristics. The purpose of this study was to determine the OS of myeloma patients seen in routine clinical practice who resembled the cohort studied in the IFM 2009 trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0163-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289963PMC
December 2018
1 Read

Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.

Blood Cancer J 2018 Dec 2;8(10):91. Epub 2018 Dec 2.

Hematology Department, Hospital Universitario La Princesa, Madrid, Spain.

Over half of chronic myeloid leukemia (CML) patients in deep molecular response do not lose the major molecular response (MMR) after stopping treatment with tyrosine kinase inhibitors (TKI). This strategy is safe in clinical trials, but its applicability in the real-life setting remains unsettled. We describe the outcomes after TKI discontinuation in a nationwide series of 236 CML patients. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0125-0
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0125-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275158PMC
December 2018
17 Reads

Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera.

Blood Cancer J 2018 Nov 26;8(12):124. Epub 2018 Nov 26.

Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative neoplasms (CRIMM), AOU Careggi, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0161-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255832PMC
November 2018
3 Reads

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.

Blood Cancer J 2018 Nov 23;8(12):123. Epub 2018 Nov 23.

service d'Hematologie, CHU de Nantes, Nantes, France.

Purpose: multiple myeloma is considered an incurable hematologic cancer but a subset of patients can achieve long-term remissions and survival. The present study examines the clinical features of long-term survival as it correlates to depth of disease response.

Patients & Methods: this was a multi-institutional, international, retrospective analysis of high-dose melphalan-autologous stem cell transplant (HDM-ASCT) eligible MM patients included in clinical trials. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0155-7
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0155-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251924PMC
November 2018
14 Reads

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea.

Blood Cancer J 2018 Nov 22;8(12):122. Epub 2018 Nov 22.

CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi, Firenze, Italy.

Refractoriness to ruxolitinib in patients with myelofibrosis (MF) was associated with clonal evolution; however, whether genetic instability is promoted by ruxolitinib remains unsettled. We evaluated the mutation landscape in 71 MF patients receiving ruxolitinib (n = 46) and hydroxyurea (n = 25) and correlated with response. A spleen volume response (SVR) was obtained in 57% and 12%, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0152-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250726PMC
November 2018
2 Reads

MPL-mutated essential thrombocythemia: a morphologic reappraisal.

Blood Cancer J 2018 Nov 20;8(12):121. Epub 2018 Nov 20.

Division of Hematology, Departments of Internal and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0159-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246562PMC
November 2018
2 Reads

Genetic predictors of response to specific drugs in primary myelofibrosis.

Blood Cancer J 2018 Nov 19;8(12):120. Epub 2018 Nov 19.

Divisions of Hematology, Departments of Internal Medicine and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0158-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242902PMC
November 2018
1 Read

Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).

Blood Cancer J 2018 Nov 19;8(12):117. Epub 2018 Nov 19.

Cancer Research Center (IBMCC-CSIC/USAL-IBSAL); Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca (USAL), Salamanca, Spain.

Here, we investigated for the first time the frequency and number of circulating tumor plasma cells (CTPC) in peripheral blood (PB) of newly diagnosed patients with localized and systemic plasma cell neoplasms (PCN) using next-generation flow cytometry (NGF) and correlated our findings with the distinct diagnostic and prognostic categories of the disease. Overall, 508 samples from 264 newly diagnosed PCN patients, were studied. CTPC were detected in PB of all active multiple myeloma (MM; 100%), and smoldering MM (SMM) patients (100%), and in more than half (59%) monoclonal gammopathy of undetermined significance (MGUS) cases (p <0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0153-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242818PMC
November 2018
12 Reads

Extramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients.

Blood Cancer J 2018 Nov 19;8(12):119. Epub 2018 Nov 19.

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0156-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242913PMC
November 2018
2 Reads

Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma.

Blood Cancer J 2018 Nov 15;8(12):116. Epub 2018 Nov 15.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

The current definition of plasma cell leukemia (PCL)- ≥ 20% circulating plasma cells (CPCs) on peripheral smear and plasma cell count ≥ 2 × 10/L-may be too stringent. We reviewed outcomes of 176 multiple myeloma (MM) patients diagnosed between 1971 and 2016, and who had CPCs detectable at diagnosis, to determine whether a lower threshold could be used to diagnose PCL. Median overall survival (mOS) was 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0140-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238010PMC
November 2018
2 Reads

Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis.

Blood Cancer J 2018 Nov 14;8(11):114. Epub 2018 Nov 14.

Département d'hématologie et immunologie biologiques, APHP, Hôpitaux universitaires Henri-Mondor, Créteil, France.

Peripheral blood monocytes include three subsets defined by CD14 and CD16 surface markers. An increase in the CD14CD16 classical monocyte fraction ≥ 94% of the total monocytes was proposed to rapidly and efficiently distinguish chronic myelomonocytic leukemia from reactive monocytosis. The robustness of this assay required a multicenter validation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0146-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235983PMC
November 2018
2 Reads

Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.

Blood Cancer J 2018 11 12;8(11):113. Epub 2018 Nov 12.

Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Given the vast phenotypic and genetic heterogeneity of acute and chronic myeloid malignancies, hematologists have eagerly awaited the introduction of next-generation sequencing (NGS) into the routine diagnostic armamentarium to enable a more differentiated disease classification, risk stratification, and improved therapeutic decisions. At present, an increasing number of hematologic laboratories are in the process of integrating NGS procedures into the diagnostic algorithms of patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs). Inevitably accompanying such developments, physicians and molecular biologists are facing unexpected challenges regarding the interpretation and implementation of molecular genetic results derived from NGS in myeloid malignancies. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0148-6
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0148-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232163PMC
November 2018
8 Reads

Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases.

Blood Cancer J 2018 Nov 12;8(11):112. Epub 2018 Nov 12.

FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.

We collected 1500 patients with myeloproliferative neoplasms (MPN) and arterial or venous thrombosis (935/565), pooling three independent cohorts previously reported. Long-term treatment with antiplatelet drugs or vitamin K-antagonists (VKA) was given to 1391 (92.7%) patients; 975 (65%) patients received hydroxyurea (HU). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0151-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232117PMC
November 2018
1 Read

Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma.

Blood Cancer J 2018 Nov 12;8(11):110. Epub 2018 Nov 12.

Division of Hematology, Department of Internal-Medicine Mayo Clinic, Rochester, MN, 55905, USA.

Peripheral T cell lymphomas (PTCL) is a heterogenous group of non-Hodgkin lymphoma and many patients remain refractory to the frontline therapy. Identifying new prognostic markers and treatment is an unmet need in PTCL. We analyzed phospho-STAT3 (pSTAT3) expression in a cohort of 169 PTCL tumors and show overall 38% positivity with varied distribution among PTCL subtypes with 27% (16/59) in PTCL-NOS; 29% (11/38) in AITL, 57% (13/28) in ALK-negative ALCL, and 93% in ALK-pos ALCL (14/15), respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0138-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232096PMC
November 2018
7 Reads

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.

Blood Cancer J 2018 Nov 9;8(11):109. Epub 2018 Nov 9.

Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Substantial improvements in survival have been seen in multiple myeloma (MM) over recent years, associated with the introduction and widespread use of multiple novel agents and regimens, as well as the emerging treatment paradigm of continuous or long-term therapy. However, these therapies and approaches may have limitations in the community setting, associated with toxicity burden, patient burden, and other factors including cost. Consequently, despite improvements in efficacy in the rigorously controlled clinical trials setting, the same results are not always achieved in real-world practice. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0141-0
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0141-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226527PMC
November 2018
18 Reads

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.

Blood Cancer J 2018 Nov 8;8(11):108. Epub 2018 Nov 8.

Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

Lenalidomide-RCHOP (R2-CHOP21) has been shown to be safe and effective in patients with untreated diffuse large B-cell lymphoma (DLBCL). The aim of this analysis is to report long-term outcome and toxicities in newly diagnosed DLBCL patients who received R2-CHOP21 in two independent phase 2 trials, conducted by Mayo Clinic (MC) and Fondazione Italiana Linfomi (FIL). All patients received R-CHOP21 plus lenalidomide. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0145-9
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0145-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224549PMC
November 2018
3 Reads

Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.

Blood Cancer J 2018 Nov 8;8(11):105. Epub 2018 Nov 8.

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium.

Progression of multiple myeloma (MM) is largely dependent on the bone marrow (BM) microenvironment wherein communication through different factors including extracellular vesicles takes place. This cross-talk not only leads to drug resistance but also to the development of osteolysis. Targeting vesicle secretion could therefore simultaneously ameliorate drug response and bone disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0139-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224554PMC
November 2018
2 Reads

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.

Blood Cancer J 2018 Nov 8;8(11):106. Epub 2018 Nov 8.

Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.

We retrospectively reviewed all patients (n = 243) receiving bortezomib, lenalidomide, and dexamethasone (VRd) induction followed by autologous stem cell transplantation (ASCT) for multiple myeloma at the Mayo Clinic between January 2010 and April of 2017. Median age was 61 (interquartile range, 55-67) with 62% of patients being male. High-risk cytogenetic abnormalities (HRA) were present in 34% of patients. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0147-7
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0147-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224498PMC
November 2018
13 Reads
2.884 Impact Factor

Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms.

Blood Cancer J 2018 Nov 7;8(11):103. Epub 2018 Nov 7.

Fondazione Policlinico Universitario A. Gemelli IRCCS, and Istituto di Ematologia, Università Cattolica del Sacro Cuore, Roma, Italy.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0143-y
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0143-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221886PMC
November 2018
8 Reads

Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study.

Blood Cancer J 2018 Nov 7;8(11):102. Epub 2018 Nov 7.

Sorbonne Universities, Faculty of Medicine, Cancer, Haemostasis and Angiogenesis Research Group, INSERM U938, Institut Universitaire de Cancérologie, Paris, France.

Venous thromboembolism (VTE) is a common complication in newly diagnosed symptomatic multiple myeloma (NDMM) patients. We explored cellular and plasma hypercoagulability in NDMM patients to identify relevant biomarkers that can be used in combination with clinical factors in the development of a risk assessment model (RAM) for VTE. Untreated patients (n = 144) with NDMM were prospectively enrolled, baseline biomarkers prior to anti-myeloma treatment and thromboprophylaxis initiation were obtained. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0135-y
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0135-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221885PMC
November 2018
10 Reads

Prefibrotic myelofibrosis: treatment algorithm 2018.

Blood Cancer J 2018 Nov 7;8(11):104. Epub 2018 Nov 7.

FROM Research Foundation, ASST Papa Giovanni XXIII, Bergamo, Italy.

Prefibrotic myelofibrosis (pre-PMF) is a distinct entity among chronic myeloproliferative neoplasm diagnosed according to the revised 2016 WHO classification. The clinical picture is heterogeneous, ranging from isolated thrombocytosis, mimicking essential thrombocythemia (ET), to symptoms of high-risk PMF. Retrospective studies showed that survival of patients with pre-PMF is worse than that of ET and better than overt PMF. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0142-z
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0142-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221891PMC
November 2018
25 Reads

Deferred autologous stem cell transplantation in systemic AL amyloidosis.

Blood Cancer J 2018 Nov 5;8(11):101. Epub 2018 Nov 5.

National Amyloidosis Centre, University College London, London, UK.

High-dose melphalan with autologous stem cell transplantation (ASCT) can induce durable haematological and organ responses in systemic AL amyloidosis (AL). Stringent selection criteria have improved safety of ASCT in AL but most patients are transplant-ineligible. We report our experience of deferred ASCT in AL patients who were transplant-ineligible at presentation but had improvements in organ function after induction chemotherapy, enabling them to undergo ASCT. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0137-9
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0137-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218452PMC
November 2018
11 Reads

CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma.

Blood Cancer J 2018 Oct 22;8(11):99. Epub 2018 Oct 22.

Department of Pathology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

CD26, a 110-kDa transmembrane glycoprotein that is expressed on several tumor cells including malignant lymphoma, has been implicated in tumorigenesis: however, little is known regarding its role in multiple myeloma (MM). Recently, we identified CD26 expression on human osteoclasts (OCs) and demonstrated that humanized IgG monoclonal antibody targeting CD26, huCD26mAb, inhibits human OC differentiation. Herein, we show that CD26 expression was present on plasma cells in the bone marrow tissues of MM patients. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41408-018-0127-y
Publisher Site
http://dx.doi.org/10.1038/s41408-018-0127-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197267PMC
October 2018
7 Reads